Tezepelumab in real-world US patients with severe asthma across phenotypes and underrepresented populations: the phase 4 PASSAGE study.

doi:10.1093/ajrccm/aamag225

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Tezepelumab in real-world US patients with severe asthma across phenotypes and underrepresented populations: the phase 4 PASSAGE study.

American journal of respiratory and critical care medicine - 1 Sept 2026

Lugogo Njira L, Akuthota Praveen, Sumino Kaharu, Burnette Autumn F, Mathur Sameer K, Lindsley Andrew W, Llanos Jean-Pierre, Marchese Claudio, Ambrose Christopher S, Emmanuel Benjamin

Abstract excerpt

RATIONALE: Clinical trials of severe asthma therapies often exclude or underrepresent key patient populations. OBJECTIVES: To evaluate the effectiveness and safety of tezepelumab in a diverse, real-world US population with severe, uncontrolled asthma (SUA). METHODS: PASSAGE was a phase 4, multicenter, single-arm, open-label, 12-month study enrolling patients with SUA (≥12 years old), including different...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adolescent
Share to Aged

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Anti-Asthmatic Agents

Share to Asthma

Share to Phenotype

Share to Severity of Illness Index

Share to Treatment Outcome

Share to United States

Source

Open in PubMed Open full text

Identifiers

PMID: 42148905
DOI: 10.1093/ajrccm/aamag225
PMCID: PMC13519350

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.